TG Therapeutics disclosed preliminary revenue figures for the fourth quarter of 2025 and a full‑year outlook that exceed prior guidance and analyst expectations. U.S. Briumvi net product revenue for Q4 2025 is projected at $182 million, up 76% from $103.6 million in Q4 2024. Full‑year 2025 U.S. Briumvi revenue is estimated at $594 million, a 9% increase over the company’s own raised guidance of $585 million and a $8 million beat over the analyst consensus of $606.03 million. Global full‑year revenue is expected to reach $616 million, surpassing the prior guidance of $600 million and the consensus estimate of $606.03 million.
The company’s 2026 revenue outlook of $875–$900 million, with U.S. Briumvi net revenue of $825–$850 million, aligns closely with the analyst consensus of $895.6 million. The guidance lift reflects confidence in continued market penetration, driven by strong demand for Briumvi in relapsing multiple sclerosis and the anticipated launch of a consolidated IV dosing regimen and a self‑administered subcutaneous formulation.
Management attributes the revenue beat to a combination of pricing power, expanded market share, and a favorable mix of high‑margin sales. CEO Michael S. Weiss noted that “Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi‑billion dollar opportunity for BRIUMVI.” He added that the company’s pipeline, including the allogeneic CAR‑T program azer‑cel, provides additional growth levers beyond the MS indication.
Analysts highlighted the revenue beat and optimistic outlook as evidence of robust execution. The company’s guidance increase from the November 2025 update signals that management expects sustained demand growth and that the new formulations will accelerate sales in the near term.
While the company remains heavily reliant on Briumvi, it is actively pursuing new indications and product formats to diversify its revenue base. The announced guidance, combined with the strong Q4 performance, suggests that TG Therapeutics is well positioned to maintain its growth trajectory and to capitalize on emerging opportunities in autoimmune indications.
Overall, the preliminary results and forward guidance demonstrate a solid operational performance, strong market traction for Briumvi, and a clear path for continued expansion, reinforcing investor confidence in the company’s long‑term prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.